Southcross Energy Partners, L.P., together with its subsidiaries, provides natural gas gathering, processing, treating, compression, and transportation services in the United States. The company has market cap of $132.68 million. The firm also offers natural gas liquid fractionation and transportation services. It currently has negative earnings. In addition, it supplies natural gas to industrial, commercial, and power generation customers, as well as local distribution companies.
The stock of Yield10 Bioscience, Inc. (NASDAQ:YTEN) hit a new 52-week low and has $1.98 target or 5.00% below today’s $2.09 share price. The 5 months bearish chart indicates high risk for the $7.22 million company. The 1-year low was reported on Dec, 1 by Barchart.com. If the $1.98 price target is reached, the company will be worth $361,000 less. The stock decreased 9.31% or $0.2142 during the last trading session, reaching $2.0858. About 16,892 shares traded. Yield10 Bioscience, Inc. (NASDAQ:YTEN) has 0.00% since December 1, 2016 and is . It has underperformed by 16.70% the S&P500.
Freestone Capital Holdings Llc holds 0.08% of its portfolio in Southcross Energy Partners, L.P. for 311,688 shares. Quinn Opportunity Partners Llc owns 22,889 shares or 0.01% of their US portfolio. Moreover, Acadian Asset Management Llc has 0% invested in the company for 166,151 shares. The North Carolina-based Bank Of America Corp De has invested 0% in the stock. California Public Employees Retirement System, a California-based fund reported 18,400 shares.
The stock increased 1.64% or $0.03 during the last trading session, reaching $1.66. About 43,699 shares traded. Southcross Energy Partners, L.P. (SXE) has risen 119.90% since December 1, 2016 and is uptrending. It has outperformed by 103.20% the S&P500.
Yield10 Bioscience, Inc., an agricultural bioscience company, engages in developing disruptive technologies for enhancing crop yield in the United States. The company has market cap of $7.22 million. It is developing various yield traits using proprietary advanced biotechnology trait gene discovery platforms. It currently has negative earnings. The firm was formerly known as Metabolix, Inc. and changed its name to Yield10 Bioscience, Inc. in January 2017.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.